查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464900

比伐卢定市场：按剂型、应用和最终用途 - 2024-2030 年全球预测

Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年比伐卢定市场规模为12.3亿美元，预计2024年将达13.1亿美元，2030年将达到18.7亿美元，复合年增长率为6.13%。

比伐卢定是一种主要用作抗凝血剂的药物，有助于防止血栓形成。比伐卢定属于一类称为直接凝血酶抑制剂的药物，可减少血管中形成血栓的机会。这在血栓可能导致严重健康问题（例如心臟病、中风以及动脉和静脉阻塞）的情况下尤其重要。世界各地心臟病的增加增加了对有效治疗方法，包括血管成形术，比伐卢定在其中发挥关键作用。此外，製剂创新在提高比伐卢定疗效和减少副作用方面具有巨大潜力，从而催生了更有效、更安全的抗凝血剂选择。然而，比伐卢定的高成本和相关的医疗程序限制了其对更广泛患者群体的可用性。此外，替代抗凝血剂和新药进入市场可能会对最终用户采用比伐卢定带来挑战。然而，医疗基础设施投资和支出的增加以及心血管疾病负担的增加正在推动先进药物的采用。随着研究继续探索比伐卢定与其他药物的组合，我们期望在未来几年开拓新的治疗领域并扩大比伐卢定的使用。

主要市场统计
基准年[2023] 12.3亿美元
预测年份 [2024] 13.1亿美元
预测年份 [2030] 18.7亿美元
复合年增长率（%） 6.13%

型态: 比伐卢定注射液经常在外科手术过程中使用。

注射用比伐卢定主要用于急性期，例如外科手术期间或医院内，并提供即时抗凝血作用。注射剂起效迅速，这对于突发和高风险的凝血情况至关重要。粉末状比伐卢定通常是首选，因为与预混合料相比，弹性且保质期更长。这种剂型对于非紧急情况或需要根据个别患者需求精确调整剂量的客製化给药方案是有利的。注射剂在紧急性和即时使用方面的便利性是无与伦比的，特别是在重症加护和手术环境中。另一方面，粉末製剂具有在使用前立即製备药物、满足特定剂量需求并消除浪费的多功能性和经济性。

最终用途：比伐卢定在门诊手术中心的新用途

门诊手术中心 (ASC) 越来越成为不需要住宿的小型手术的首选。比伐卢定在 ASC 中的使用主要围绕其最低监测要求、快速作用和短半衰期，这使其适合门诊病人环境。由于比伐卢定在急诊环境中的广泛用途，医院和诊所是比伐卢定的主要使用者。在医院和诊所，比伐卢定用于更广泛和侵入性的心血管手术，其快速起效和可逆性使其非常有益。专科诊所，特别是循环系统科诊所，经常在接受诊断性心导管插入术和其他非手术干预的患者中使用比伐卢定。

区域洞察

由于心臟病的高发病率和发达的医疗基础设施，美洲对比伐卢定的需求正在增加。客户的购买行为倾向于信任经过临床验证的药物，其中比伐卢定因其可有效减少出血併发症而受到青睐。欧洲国家对比伐卢定采取了统一的方法，该方法深受欧盟 (EU) 法规和医疗保健指南的影响。采用情况因每个国家的医疗保健系统、可用性和报销政策而异。在欧盟（EU），由于人口老化和心血管疾病的增加，对比伐卢定的需求正在稳步增加。在中东和非洲，由于医疗保健投资的增加以及与国际医疗机构的合作，比伐卢定市场正在兴起。由于政府的医疗改革措施和对医院基础设施的投资，亚太地区是比伐卢定的一个充满活力的市场。

FPNV定位矩阵

FPNV定位矩阵对于评估比伐卢定市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对比伐卢定市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 比伐卢定市场规模及预测是多少？

2.比伐卢定市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.比伐卢定市场的技术趋势和法规结构是什么？

4.比伐卢定市场主要厂商的市场占有率为何？

5. 进入比伐卢定市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对治疗心血管疾病的有效抗凝血剂的需求日益增长。
      • 增加消费者在药品和药品改善的支出
    • 抑制因素
      • 与其他选择相比，比伐卢定价格昂贵
    • 机会
      • 即用型比伐卢定组合药物的开发
      • 新产品持续获得政府核准
    • 任务
      • 与使用比伐卢定相关的风险和併发症
  • 市场区隔分析
    • 剂型：比伐卢定通常在手术期间以注射剂的形式使用。
    • 最终用途：比伐卢定在门诊手术中心的新用途
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 比伐卢定市场（依剂型划分）

  • 注射
  • 粉末

第七章 比伐卢定市场：依应用分类

  • 血管成形术
  • 肝素诱发的血小板减少性疾病
  • 经皮冠状动脉介入治疗

第八章比伐卢定市场：依最终用途

  • 门诊手术中心
  • 医院/诊所
  • 专科诊所

第九章 北美、南美洲比伐卢定市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区比伐卢定市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲比伐卢定市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Avenacy 推出非专利药比伐卢定注射液，扩大了美国抗凝血药物的选择
    • Endo International推出即用型比伐卢定注射液以提高临床效率
    • 远藤国际宣布建立战略联盟，分销美国即用型比伐卢定注射液
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-7A22CB0E5BB3

[189 Pages Report] The Bivalirudin Market size was estimated at USD 1.23 billion in 2023 and expected to reach USD 1.31 billion in 2024, at a CAGR 6.13% to reach USD 1.87 billion by 2030.

Bivalirudin is a medication primarily used as an anticoagulant, which helps prevent blood clot formation. Bivalirudin belongs to a class of drugs known as direct thrombin inhibitors, which reduces the likelihood of clots forming in the blood vessels. This is especially important in situations where blood clots can lead to severe health issues such as heart attacks, strokes, or blockages in the arteries or veins. An increase in the global incidence of heart diseases has led to a higher need for effective treatment options, including angioplasty, where bivalirudin plays a critical role. Moreover, the significant potential for innovation in formulating bivalirudin to enhance its efficacy and reduce side effects led to more effective and safer anticoagulant options. However, the high cost of bivalirudin and related medical procedures limit its accessibility to a broader patient base. In addition, the presence of alternative anticoagulants and new drugs entering the market may challenge bivalirudin adoption among end-users. Nevertheless, an increase in healthcare infrastructure investments and spending, along with a rising burden of cardiovascular diseases, is improving the adoption of advanced drug medications. The ongoing exploration of bivalirudin in combination with other drugs is expected to open new therapeutic areas and extend the application of bivalirudin in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.31 billion
Forecast Year [2030] USD 1.87 billion
CAGR (%) 6.13%

Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures

The injectable form of bivalirudin is primarily used in acute settings, such as during surgical procedures or in hospitals, to provide immediate anticoagulation effects. Injection form is beneficial for rapid onset of action, which is crucial for sudden, high-risk clotting conditions. The powder form of bivalirudin offers flexibility in dosing and is often preferred for its longer shelf-life compared to premixed solutions. This form is advantageous in less urgent scenarios or for tailored dosing regimens, where precise adjustments in dosage are required to meet patients' individual needs. The injectable form is unmatched in urgency and convenience for immediate use, especially in critical care and surgical settings. Meanwhile, the powder form offers versatility and economy for situations allowing for the preparation of the drug just before use, catering to specific dosage needs, and reducing wastage.

End-Use: Emerging usage of bivalirudin in ambulatory surgical centers

Ambulatory surgical centers (ASCs) have increasingly become preferred for minor surgical procedures that don't require an overnight stay. The use of bivalirudin in ASCs primarily revolves around its minimal monitoring requirements, quick action, and shorter half-life, which makes it suitable for outpatient settings. Hospitals & clinics are the primary users of bivalirudin, given the wide range of applications in acute care settings. Hospitals and clinics use bivalirudin for more extensive and invasive cardiovascular procedures, where its quick onset and reversibility are highly beneficial. Specialty clinics, particularly those focused on cardiology, often utilize bivalirudin for patients undergoing diagnostic cardiac catheterization or other non-surgical interventions.

Regional Insights

The high prevalence of heart diseases and the advanced healthcare infrastructure stimulate the need for bivalirudin in the Americas. Customer purchasing behavior leans towards trust in clinically proven medications, with bivalirudin being preferred for its efficiency in reducing bleeding complications. European countries showcase a uniform approach towards Bivalirudin, which has been greatly influenced by European Union (EU) regulations and healthcare guidelines. The adoption varies with national healthcare systems, availability, and reimbursement policies. The growing aging population and an increase in cardiovascular diseases underscore a steady need for bivalirudin in the European Union (EU). In the Middle East and Africa, the market for Bivalirudin is emerging due to increasing investments in healthcare and collaborations with international health organizations. The Asia Pacific region represents a dynamic market for bivalirudin due to the government's push towards healthcare reform and investment in hospital infrastructure.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bivalirudin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bivalirudin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy's Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bivalirudin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Dosage Form
    • Injection
    • Powder
  • Application
    • Angioplasty
    • Heparin-induced Thrombocytopenia
    • Percutaneous Coronary Intervention
  • End-Use
    • Ambulatory Surgical Centers
    • Hospitals & Clinics
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bivalirudin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bivalirudin Market?

3. What are the technology trends and regulatory frameworks in the Bivalirudin Market?

4. What is the market share of the leading vendors in the Bivalirudin Market?

5. Which modes and strategic moves are suitable for entering the Bivalirudin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
      • 5.1.1.2. Growing consumer expenditure for improved drug and medications
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
      • 5.1.3.2. Ongoing government approvals for new products
    • 5.1.4. Challenges
      • 5.1.4.1. Risks and complexities associated with use of bivalirudin
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
    • 5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bivalirudin Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Injection
  • 6.3. Powder

7. Bivalirudin Market, by Application

  • 7.1. Introduction
  • 7.2. Angioplasty
  • 7.3. Heparin-induced Thrombocytopenia
  • 7.4. Percutaneous Coronary Intervention

8. Bivalirudin Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Clinics

9. Americas Bivalirudin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bivalirudin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bivalirudin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
    • 12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
    • 12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
  • FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIVALIRUDIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023